8,9,12 Given the significant burden these serious diseases place on patients, their families, and caregivers, there is a need for alternative treatment options that may effectively relieve the signs ...

Prurigo nodularis (PN ... but abnormalities in the nerves and immune system cells located in the top and middle layers of the skin (the epidermis and dermis) seem to be the cause. Historically, it was ...

Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the ...

A monoclonal antibody, nemolizumab is intended to treat adults with moderate-to-severe prurigo nodularis. Credit: Kwangmoozaa / Shutterstock. Galderma has reported that the randomised Phase III ...

Autoimmune diseases are conditions in which your immune system mistakenly damages healthy cells in your body. Types include rheumatoid arthritis, Crohn’s disease, and some thyroid conditions.

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with moderate-to-severe prurigo nodularis (PN), has achieved both ...

What is Known About the Estrogen Deficiency of Menopause & Specific Autoimmune Diseases It is known that many natural, pathological and therapeutic conditions can change serum estrogen levels ...

Autoimmune disease rashes can occur when the immune system mistakenly attacks the body's cells, tissues, and organs. An autoimmune disease rash can indicate a flare-up (times of increased disease ...

About prurigo nodularis Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body ...

Recent studies have unveiled a disturbing connection between air pollution and autoimmune diseases, affecting millions of Americans living in areas with compromised air quality. This emerging ...

Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology ...